13 results
8-K
EX-99.1
RNXT
RenovoRx Inc
14 Nov 22
RenovoRx Reports Third Quarter 2022 Financial Results
8:45am
(RenovoTAMP®) therapy platform, today reported its financial results for the quarter ended September 30, 2022.
“Since our Inception, RenovoRx’s mission … is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead
8-K
EX-99.1
RNXT
RenovoRx Inc
27 Apr 23
Departure of Directors or Certain Officers
8:30am
, clinical biopharmaceutical company with a vision to disrupt the current paradigm of biopharmaceutical treatments. Our mission is to lead a revolution
8-K
EX-99.1
RNXT
RenovoRx Inc
3 Apr 23
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:45pm
with a vision to disrupt the current paradigm of cancer treatment. Our mission is to lead a revolution in oncology therapy by delivering its innovative
8-K
EX-99.1
RNXT
RenovoRx Inc
19 Sep 22
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
8:45am
and Controller. With the addition of Angela, we are rounding out our leadership team, to accelerate our stated mission to build RenovoRx into a leader
8-K
EX-99.1
RNXT
RenovoRx Inc
19 Jul 22
RenovoRx Appoints James Ahlers as Chief Financial Officer
8:45am
and dedication to our mission and goals. We wish Chris well as he moves onto his next chapter.”
Mr. Bagai added, “As our team looks forward, we
8-K
EX-99.1
rs2hoa wg
15 May 23
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
8:30am
8-K
EX-99.1
k2w1zj7cfno
14 Nov 23
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
12:00am
8-K
EX-10.1
ehveqa8nd
14 Mar 24
Departure of Directors or Certain Officers
4:53pm
424B3
hu9gy64m
19 May 23
Prospectus supplement
5:07pm
424B5
3480xi
3 Apr 23
Prospectus supplement for primary offering
9:00am
- Prev
- 1
- Next